targeted immune system activation

introduction to ISA

ISA Pharmaceuticals develops targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections.

feature

ISA101b and cemiplimab (Libtayo®) study in patients with platinum refractory HPV16 positive oropharyngeal cancer (OPC). Read more.